While personalized CAR-T cancer therapies make headlines in biotech, Amgen has been betting big on another tumor-killing approach with, yes, another acronym: BiTEs.

The trademarked term stands for a bi-specific T-cell engager — an antibody that can grab both immune cells and tumor cells and help encourage the body’s natural defenses to produce tumor-killing proteins. The Food and Drug Administration has already approved one of Amgen’s BiTE-based therapies, Blincyto, for the treatment of acute lymphoblastic leukemia. And the company is pushing forward with BiTEs for treating other types of cancer, like multiple myeloma, glioblastoma, and other solid tumors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy